AllAnalyst Report
logoMorningstarSeptember 30, 2024

BridgeBio Pharma, Inc.: BridgeBio: Key Pipeline Candidate Acoramidis Drives Valuation for Long-Term Investors

Symbols
BBIO
Sector(s)
Healthcare
Rating
Current Price
$24.97
Fair Value
Economic Moat
Stewardship
Summary

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered sm

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade